Literature DB >> 21843944

Patients 35 years old or younger with operable breast cancer are more at risk for relapse and survival: a retrospective matched case-control study.

Roujun Peng1, Shusen Wang, Yanxia Shi, Donggen Liu, Xiaoyu Teng, Tao Qin, Yixin Zeng, Zhongyu Yuan.   

Abstract

It has long been suggested that younger women with breast cancer have less favorable prognostic factors and poorer outcomes. Our main objectives were to determine whether poor prognosis among young women was independent of other common clinicopathologic parameters. We retrospectively analyzed 551 young patients (≤ 35 years, Group I) and 551 older patients (36-50 years, Group II), matched for year of diagnosis, family history of breast cancer, pathologic stage, hormone receptor expression and application of adjuvant therapy. Patients in Group I had significantly shorter disease-free survival (DFS) than Group II (median 23.2 months vs. 28.4 months, P = 0.024). Five-year DFS rate(63.7% vs. 74.7%, P < 0.001) and overall survival (OS) rate (79.5% vs. 85.6%, P = 0.024) in Group I was inferior to those in Group II. Multivariate analysis showed that young age was a significantly negative predictor for DFS and OS. Our study thus shows that age (≤ 35 y/o) is an independent risk factor for prognosis in operable breast cancer.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21843944     DOI: 10.1016/j.breast.2011.07.012

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  17 in total

1.  Profiling the immune stromal interface in breast cancer and its potential for clinical impact.

Authors:  Sheeba Irshad; Anita Grigoriadis; Katherine Lawler; Tony Ng; Andrew Tutt
Journal:  Breast Care (Basel)       Date:  2012-08       Impact factor: 2.860

Review 2.  Biologic and clinical characteristics of adolescent and young adult cancers: Acute lymphoblastic leukemia, colorectal cancer, breast cancer, melanoma, and sarcoma.

Authors:  James V Tricoli; Donald G Blair; Carey K Anders; W Archie Bleyer; Lisa A Boardman; Javed Khan; Shivaani Kummar; Brandon Hayes-Lattin; Stephen P Hunger; Melinda Merchant; Nita L Seibel; Magdalena Thurin; Cheryl L Willman
Journal:  Cancer       Date:  2016-02-05       Impact factor: 6.860

3.  Prognostic Significance of Adjuvant Chemotherapy Induced Amenorrhea in Luminal A and B Subtypes.

Authors:  Çetin Ordu; Kezban Nur Pilancı; Gül Alço; Filiz Elbüken; Ülkühan İner Köksal; Serkan İlgun; Dauren Sarsenov; Ayşe Esra Aydın; Alper Öztürk; Zeynep İyigün Erdoğan; Filiz Ağaçayak; Fatmagül Çubuk; Coşkun Tecimer; Yeşim Eralp; Tomris Duymaz; Fatma Aktepe; Vahit Özmen
Journal:  Eur J Breast Health       Date:  2018-07-01

4.  Clinicopathological characteristics and treatment of young women with breast cancer in China: a nationwide multicenter 10-year retrospective study.

Authors:  Wei Zhang; Bai-Lin Zhang; Jian-Jun He; Jin-Hu Fan; Jing Li; Bin Zhang; Hong-Jian Yang; Xiao-Ming Xie; Zhong-Hua Tang; Hui Li; Jia-Yuan Li; Shu-Lian Wang; You-Lin Qiao; Rong Huang; Pin Zhang
Journal:  Gland Surg       Date:  2021-01

5.  Ovarian Ablation Using Goserelin Improves Survival of Premenopausal Patients with Stage II/III Hormone Receptor-Positive Breast Cancer without Chemotherapy-Induced Amenorrhea.

Authors:  Juan Zhou; San-Gang Wu; Jun-Jie Wang; Jia-Yuan Sun; Feng-Yan Li; Qin Lin; Huan-Xin Lin; Zhen-Yu He
Journal:  Cancer Res Treat       Date:  2014-08-21       Impact factor: 4.679

6.  Post-mastectomy radiotherapy can improve survival in breast cancer patients aged 35 years or younger with four or more positive nodes but not in one to three positive nodes.

Authors:  Sangang Wu; Qun Li; Juan Zhou; Jiayuan Sun; Fengyan Li; Qin Lin; Zhenyu He
Journal:  Ther Clin Risk Manag       Date:  2014-10-09       Impact factor: 2.423

7.  The Prognostic Impact of Molecular Subtypes and Very Young Age on Breast Conserving Surgery in Early Stage Breast Cancer.

Authors:  Cetin Ordu; Kandace McGuire; Gul Alco; Kezban Nur Pilanci; Ulkuhan I Koksal; Filiz Elbüken; Zeynep Erdogan; Filiz Agacayak; Serkan Ilgun; Dauren Sarsenov; Alper Öztürk; Şefik İğdem; Sait Okkan; Yeşim Eralp; Maktav Dincer; Vahit Ozmen
Journal:  Cureus       Date:  2016-06-07

8.  Comprehensive analysis of BRCA1, BRCA2 and TP53 germline mutation and tumor characterization: a portrait of early-onset breast cancer in Brazil.

Authors:  Dirce Maria Carraro; Maria Aparecida Azevedo Koike Folgueira; Bianca Cristina Garcia Lisboa; Eloisa Helena Ribeiro Olivieri; Ana Cristina Vitorino Krepischi; Alex Fiorini de Carvalho; Louise Danielle de Carvalho Mota; Renato David Puga; Maria do Socorro Maciel; Rodrigo Augusto Depieri Michelli; Eduardo Carneiro de Lyra; Stana Helena Giorgi Grosso; Fernando Augusto Soares; Maria Isabel Alves de Souza Waddington Achatz; Helena Brentani; Carlos Alberto Moreira-Filho; Maria Mitzi Brentani
Journal:  PLoS One       Date:  2013-03-01       Impact factor: 3.240

9.  The value of radiotherapy in breast cancer patients with isolated ipsilateral supraclavicular lymph node metastasis without distant metastases at diagnosis: a retrospective analysis of Chinese patients.

Authors:  San-Gang Wu; Jia-Yuan Sun; Juan Zhou; Feng-Yan Li; Qin Lin; Huan-Xin Lin; Zhen-Yu He
Journal:  Onco Targets Ther       Date:  2014-02-15       Impact factor: 4.147

10.  MicroRNAs discriminate familial from sporadic non-BRCA1/2 breast carcinoma arising in patients ≤35 years.

Authors:  Elen Pereira Bastos; Helena Brentani; Fatima Solange Pasini; Aderbal Ruy T Silva; Cesar Henrique Torres; Renato David Puga; Eloisa Helena Ribeiro Olivieri; Amanda Rusiska Piovezani; Carlos Alberto de Bragança Pereira; Ariane Machado-Lima; Dirce Maria Carraro; Maria Mitzi Brentani
Journal:  PLoS One       Date:  2014-07-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.